Bicycle Therapeutics plc Finance Lease, Right-of-Use Asset, Amortization
Bicycle Therapeutics plc (BCYC) reported Finance Lease, Right-of-Use Asset, Amortization of $56.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-07-30
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $56.00K, a 1.82% increase year-over-year.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $55.00K, a 5.77% increase year-over-year.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $55.00K, a 3.77% increase year-over-year.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $55.00K.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for fiscal 2025 was $217.00K, a 309.43% increase from fiscal 2024.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for fiscal 2024 was $53.00K.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00.
- Bicycle Therapeutics plc finance lease, right-of-use asset, amortization for fiscal 2022 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.00K 10-Q · filed 2026-07-30 | $111.00K 10-Q · filed 2026-07-30 | $166.00K derived: sum of 3 quarters · filed 2026-07-30 | $221.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $55.00K 10-Q · filed 2026-04-30 | $110.00K derived: sum of 2 quarters · filed 2026-04-30 | $165.00K derived: sum of 3 quarters · filed 2026-04-30 | $220.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $110.00K derived: sum of 2 quarters · filed 2026-03-17 | $165.00K derived: sum of 3 quarters · filed 2026-07-30 | $217.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $55.00K 10-Q · filed 2025-10-30 | $110.00K derived: sum of 2 quarters · filed 2026-07-30 | $162.00K 10-Q · filed 2025-10-30 | $215.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $55.00K 10-Q · filed 2026-07-30 | $107.00K 10-Q · filed 2026-07-30 | $160.00K derived: sum of 3 quarters · filed 2026-07-30 | $160.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $52.00K 10-Q · filed 2026-04-30 | $105.00K derived: sum of 2 quarters · filed 2026-04-30 | $105.00K derived: sum of 3 quarters · filed 2026-04-30 | $105.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $53.00K derived: sum of 2 quarters · filed 2026-03-17 | $53.00K derived: sum of 3 quarters · filed 2026-03-17 | $53.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |